nach oben

Journal of Gastrointestinal Cancer

Erschienen in:

26.01.2017 | Brief Communication

Epigenetic Downregulation of PTEN in Gallbladder Cancer

verfasst von: Dinesh Singh Tekcham, Sanjeev Gupta, Braj Raj Shrivastav, Pramod Kumar Tiwari

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Gallbladder cancer (GBC) is becoming a global health problem. Phosphatase and tensin homolog (PTEN), also known as guardian gene of cancer, encodes a protein, which dephosphorylates phosphatidylinositol (3,4,5) triphosphate {PtdIns (3,4,5) P3 } into phosphatidylinositol (4,5) diphosphate {PtdIns (4,5) P2} that results in the inhibition of AKT/PKB signaling pathway. PTEN plays a key role in the pathogenesis of various cancers. However, its role in GBC is still obscure. The present study was aimed to identify the epigenetic role of PTEN in GBC and GSD.

Methods

PTEN promoter methylation was studied by methylation-specific PCR in 50 GBC and 30 GSD tissues. Transcript level expression of PTEN was analyzed by reverse transcriptase PCR and quantitative PCR in 20 GBC and 20 GSD tissue samples. Immunohistochemistry was performed on tissue microarrays of 136 GBC samples to correlate the methylation pattern with the pattern of in situ expression of PTEN protein. Student’s t test was performed to test the significant level of difference between case and control samples. Values showing p ≤ 0.05 were considered significant.

Results

MS PCR showed PTEN promoter methylation in 30% (15/50) GBC (p = 0.0486) and 22.86% (8/30) GSD (p = 0.0530) cases. RT-PCR and qPCR revealed downregulation of PTEN in advanced GBC cases (p < 0.0001), but, not in GSD (p = 0.901). Immunohistochemistry of GBC tissue microarray scored 1+ in 20.29% (p = 0.0028) and zero or negative in 50% (p < 0.0001) GBC cores.

Conclusions

Thus, PTEN may be considered as a useful biomarker for the management of GBC, however, needs larger sample size to validate it further.

Nur mit Berechtigung zugänglich

Barbhuiya MA, Singh TD, Gupta S, Shrivastav BR, Tiwari PK. Incidence of gall bladder cancer in rural and semi urban population of north-central India; a first insight. Internet J Epidemiol. 2009;7:2.

Randi G, Malvezzi M, Levi F, et al. Epidemiology of biliary tract cancers: an update. Ann Oncol. 2009;20:146–59.CrossRefPubMed

Singh TD, Barbhuiya MA, Poojary S, Shrivastav BR, Tiwari PK. The liver function test enzymes and glucose level are positively correlated in gallbladder cancer: a cancer registry data analysis from north central India. Indian J Cancer. 2012;49:125–36.CrossRefPubMed

Tian K, Di R, Wang L. MicroRNA-23a enhances migration and invasion through PTEN in osteosarcoma. Cancer Gene Ther. 2015; doi:10.1038/cgt.2015.27.

Cai L, Ye Y, Jiang Q, et al. Epstein-Barr virus-encode microRNA BART1 induces tumour metastasis by regulating PTEN-dependent pathways in nasopharyngeal carcinoma. Nat Commun. 2015;6:7353. doi:10.1038/ncomms8353.CrossRefPubMedPubMedCentral

Dahia PL, Marsh DJ, Zheng Z, et al. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res. 1997;57:4710–3.PubMed

Ortega-Molina A, Serrano M. PTEN in cancer, metabolism, and aging. Trends Endocrinol Metabolism. 2013;24:184–9.CrossRef

Kang YH, Lee HS, Kim WH. Promoter methylation and silencing of PTEN in gastric carcinoma. Lab Investig. 2002;82:285–91.CrossRefPubMed

Wiencke JK, Zheng S, Jelluma N, et al. Methylation of the PTEN promoter defines lowgrade gliomas and secondary glioblastoma. Neurooncol. 2007;9:271–9.

10.

Rosai J. In Rosai and Ackermans surgical pathology. Edinberg: Mosby; 2004.

11.

Sambrook J, Russel DW. Molecular cloning: a laboratory manual. 3rd ed. New York: Cold Spring Harbor Laboratory; 2001.

12.

Herman JG, Jeremy RG, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93:9821–6.CrossRefPubMedPubMedCentral

13.

Sato K, Tamura G, Tsuchiya T, et al. Analysis of genetic and epigenetic alterations of the PTEN gene in gastric cancer. Virchows Arch. 2002;440:160–5.CrossRefPubMed

14.

Shinyo Y, Kodama J, Hongo A, Yoshinouchi M, Hiramatsu Y. Heparanase expression is an independent prognostic factor in patients with invasive cervical cancer. Ann Oncol. 2003;14:1505–10.CrossRefPubMed

15.

Auwera IVD, Laere SJV, Bosch SMVD, et al. Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter is associated with the inflammatory breast cancer phenotype. British J Cancer. 2008;99:1735–42.CrossRef

16.

Singh TD, Gupta S, Shrivastav BR, Tiwari PK. Epigenetic profiling of gallbladder cancer and gallstone diseases: evaluation of tumour associated genes. Gene. 2016;576:743–52.CrossRefPubMed

17.

Wolff AC, Hammond MEH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131:18–43.PubMed

18.

Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007;129:1261–74.CrossRefPubMedPubMedCentral

19.

Goel A, Arnold CN, Niedzwiecki D, et al. Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res. 2004;64:3014–21.CrossRefPubMed

20.

Wang L, Wang WL, Zhang Y, Guo SP, Zhang J, Li QL. Epigenetic and genetic alterations of PTEN in hepatocellular carcinoma. Hepatol Res. 2007;37:389–96.CrossRefPubMed

21.

García JM, Silva J, Peña C, et al. Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes Chromosomes Cancer. 2004;41:117–24.CrossRefPubMed

22.

Yang H, Kong W, He L, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008;68:425–33.CrossRefPubMed

23.

Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterol. 2007;133:647–58.CrossRef

24.

Carver BS, Tran J, Gopalan A, et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet. 2009;41:619–24.CrossRefPubMedPubMedCentral

25.

Frisk T, Foukakis T, Dwight T, et al. Silencing of the PTEN tumor-suppressor gene in anaplastic thyroid cancer. Genes Chromosomes Cancer. 2002;35:74–80.CrossRefPubMed

26.

Teng DH, Hu R, Lin H, et al. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res. 1997;57:5221–5.PubMed

27.

Rhei E, Kang L, Bogomolniy F, Federici MG, Borgen PI, Boyd J. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res. 1997;57:3657–9.PubMed

28.

Risinger JI, Hayes K, Maxwell GL, et al. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res. 1998;4:3005–10.PubMed

29.

Yue S, Li J, Lee SY, et al. Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness. Cell Metab. 2014;19:393–406.CrossRefPubMedPubMedCentral

30.

Liu DC, Yang ZL. Overexpression of EZH2 and loss of expression of PTEN is associated with invasion, metastasis, and poor progression of gallbladder adenocarcinoma. Pathol Res Pract. 2011;207:472–8.CrossRefPubMed

31.

Ali A, Mishra PK, Sharma S, Arora A, Saluja SS. Effects of PTEN gene alteration in patients with gallbladder cancer. Cancer Genet. 2015;208:587–94.CrossRefPubMed

32.

Roa I, de Toro G, Fernández F, Game A, Muñoz S, de Aretxabala X, Javle M. Inactivation of tumor suppressor gene pten in early and advanced gallbladder cancer. Diagn Pathol. 2015;10:1.CrossRef

33.

Lv W, Wang L, Lu J, Mu J, Liu Y, Dong P. Downregulation of TPTE2P1 inhibits migration and invasion of gallbladder cancer cells. Chemical Biol Drug Design. 2015;86:656–62.CrossRef

Titel: Epigenetic Downregulation of PTEN in Gallbladder Cancer
verfasst von: Dinesh Singh Tekcham
Sanjeev Gupta
Braj Raj Shrivastav
Pramod Kumar Tiwari
Publikationsdatum: 26.01.2017
Verlag: Springer US
Erschienen in: Journal of Gastrointestinal Cancer / Ausgabe 1/2017
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-017-9919-8

Chemoradiotherapy with Brachytherapy or Electron Therapy Boost for Locally Advanced Squamous Cell Carcinoma of the Anus—Reducing the Colostomy Rate

Open Access
Original Research

Evaluation the Survival of Patients with Gastric Cancer Treated with Adjuvant or Palliative Chemotherapy

Original Research

Cost Effectiveness of Metal Stents in Relieving Obstructive Jaundice in Patients with Pancreatic Cancer

Original Research

Capecitabine-Induced Severe Toxicity Secondary to DPD Deficiency and Successful Treatment with Low Dose 5-Fluorouracil

Letter to the Editor

A Rare Case of a Gastrointestinal Stromal Tumor (GIST) Presenting as a Perforated Meckel’s Diverticulum

Case Report

Erratum to: A Case of Ruptured Adult Embryonal Sarcoma of the Liver with Excellent Outcome After Neoadjuvant Chemotherapy

Erratum

Neu im Fachgebiet Onkologie

Studie zur HIFU bei Prostatakrebs lässt viele Fragen offen

22.01.2025
Prostatakarzinom
Nachrichten

Führt eine HIFU-Ablation beim Prostatakarzinom im Vergleich mit einer radikalen Prostatektomie zu ähnlichen onkologischen, aber besseren funktionalen Ergebnissen? Interimsdaten der französischen HIFI-Studie sind uneindeutig. In einem Kommentar zur Studie werden zumindest drei allgemeine Erkenntnisse herausgearbeitet.

Adipositas als negativer Prognosefaktor bei Kindern mit Krebs

Eine kanadische Studie weist darauf hin, dass Übergewicht zum Zeitpunkt der Krebsdiagnose ein unabhängiger Risikofaktor für schlechtere Überlebenschancen bei erkrankten Kindern und Jugendlichen sein könnte. Allerdings sind nicht alle Patientinnen und Patienten gleichermaßen betroffen.

Polypen bei nahen Verwandten – erhöhtes Darmkrebsrisiko

20.01.2025
Risikofaktoren für Krebserkrankungen
Nachrichten

Werden bei erstgradigen Verwandten gutartige Darmpolypen identifiziert, ist das Risiko, selbst an einem Kolorektalkarzinom zu erkranken, deutlich erhöht – vor allem das für eine früh beginnende Erkrankung. Hier könnte sich eine frühe Koloskopie besonders lohnen.

KI-gestütztes Mammografiescreening überzeugt im Praxistest

16.01.2025
Künstliche Intelligenz im Gesundheitswesen
Nachrichten

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Epigenetic Downregulation of PTEN in Gallbladder Cancer